Arvind is an accomplished leader with over 20 years of experience in the biopharmaceutical industry. Prior to Third Arc Bio, he held pivotal roles at leading organizations including Eli Lilly, Avantor, and Medarex, where he spearheaded the development and successful commercialization of groundbreaking therapies such as ERBITUX®, CYRAMZA®, PORTRAZZA™, and LARTRUVO®.He has led teams in optimizing workflows, establishing antibody and gene therapy platforms, and implementing novel technologies that enhanced manufacturing efficiency and product stability. Among his key achievements, Arvind has managed the development of multiple monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates from preclinical stages through commercial registration and life cycle management. He has streamlined the CMC development process, reducing time to first human dose and commercial registration.

Arvind earned his PhD in chemistry from the Tata Institute of Fundamental Research and holds an MS from Banaras Hindu University. He also completed postdoctoral studies in biochemistry at the University of North Carolina at Chapel Hill.